Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1297| Title: | Brentuximab vedotin: targeting CD30 as standard in CTCL. |
| Epworth Authors: | Prince, Miles |
| Other Authors: | Gautam, Ashish Kim, Youn |
| Keywords: | ALCANZA Study Cutaneous T-Cell Lymphoma CTCL Anti-CD30 Brentuximab Vedotin Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia |
| Issue Date: | Feb-2018 |
| Publisher: | Impact Journals |
| Citation: | Oncotarget. 2018 Feb 10;9(15):11887-11888 |
| Abstract: | Editorial |
| URI: | http://hdl.handle.net/11434/1297 |
| DOI: | 10.18632/oncotarget.24472 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844715/ |
| PubMed URL: | https://www.ncbi.nlm.nih.gov/pubmed/29552279 |
| ISSN: | 1949-2553 |
| Journal Title: | Oncotarget |
| Type: | Letter |
| Copyright holder: | 2018 Prince et al. |
| Affiliated Organisations: | Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum The University of Melbourne, VIC, Australia |
| Appears in Collections: | Cancer Services |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Prince et al 2018.pdf | 662.04 kB | Adobe PDF | View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.